Experience with treating basal cell carcinoma of the occipital region with regional lymph node metastasis

«Radiation and Risk», 2020, vol. 29, No. 4, pp.126-135

DOI: 10.21870/0131-3878-2020-29-4-126-135

Authors

Abramova O.E. – Radiologist, Graduate Student. Contacts: 4 Korolyov str., Obninsk, Kaluga region, Russia, 249035. Tel.: 89208774501; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .
Gumenetskaya Yu.V. – Head of Dep., MD. A. Tsyb MRRC.
Kudryavtsev D.V. – Head of Dep., MD. CCOH N 1.

1 A. Tsyb MRRC, Obninsk
2 City Clinical Oncology Hospital N 1, Moscow

Abstract

Basal cell carcinoma (BCC) is the most common cancer of the skin, it accounts for 75-97% of all skin tumors. Nowadays, there is a wide range of local treatment options for BCC. The disease frequently occurs in the head and neck region. Because BCC tends to recur, it is necessary to find the most effective treatment option for the disease with account of cosmetic results. Although the BCC prevalence is rather high, metastatic disease occurs rarely (0,008-0,55%). Maybe it is the reason for lack of recurrent BCC patients management algorithm in the current clinical guidelines. The article presents the report of clinical observations on the development, treatment and outcomes of recurrent BCC in the occipital region with cervical lymph node metastasis. Neck lymph nodes were treated with twophase conventionally fractionated radiotherapy to the total dose of 60 Gy. For treatment of recurrent BCC in the occipital region we performed a course of external beam radiation therapy to the total dose of 66 Gy followed by the 6 month targeted therapy with the SMO inhibitor vismodegib (a smoothened transmembrane protein). There was no evidence of disease recurrence 11 months after the therapy completion. Radiotherapy in combination with targeted therapy was shown to be highly effective and safe treatment of recurrent, locally advanced BCC in the head and neck with regional lymph node metastases. The used method seems to be a reasonable alternative approach to the treatment of BCC when other conservative therapy options have been exhausted and surgical therapy is not possible.

Key words
basal cell carcinoma, BCC metastasis from basal cell carcinoma, radiotherapy, targeted therapy, recurrent basal cell carcinoma, photodynamic therapy, surgical therapy, topical therapy, basalioma, treatment of basal cell carcinoma.

References

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Basal cell skin cancer. Version 1.2020 – October 24, 2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf (Accessed 12.01.2020).

2. Jacobs G.H., Rippey J.J., Altini M. Prediction of aggressive behavior in basal cell carcinoma. Cancer, 1982, vol. 49, no. 3, pp. 533-537.

3. Jayaraman S.S., Rayhan D.J., Hazany S., Kolodney M.S. Mutational landscape of basal cell carcinomas by whole-exome sequencing. J. Invest. Dermatol., 2014, vol. 134, no. 1, pp. 213-220.

4. Goppner D., Leverkus M. Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. J. Skin Cancer, 2011, vol. 2011, pp. 1-8. DOI: 10.1155/2011/650258.

5. Tilli C.M.L.G., Van Steensel M.A.M., Krekels G.A.M., Neumann H.A.M., Ramaekers F.C.S. Molecular aeti-ology and pathogenesis of basal cell carcinoma. Br. J. Dermatol., 2005, vol. 152, no. 6, pp. 1108-1124.

6. European Handbook of Dermatological Treatments. Eds.: A.D. Katsambasa, T.M. Lotti. Moscow, MED press-inform, 2008. 724 p. (In Russian).

7. Kondrat’yeva E.G., Lamotkin I.A. Effectiveness of treatment of basal cell carcinoma. Actual problems of providing specialized medical care in a hospital setting and the use of hospital-substituting technologies: proceedings of the all-Russian scientific and practical conference December 4, 2009. Moscow, 2009. P. 18. (In Russian).

8. Rowe D.E., Carroll R.J., Day C.L.Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. Dermatol. Surg. Oncol., 1989, vol. 15, no. 3, pp. 315-343.

9. Thissen M.R., Neumann M.H., Schouten L.J. A systematic review of treatment modalities for primary ba-sal cell carcinomas. Arch. Dermatol., 1999, vol. 135, no. 10, pp. 1177-1183.

10. Rhodes L.E., de Rie M.A., Leifsdottir R., Yu R.C., Bachmann I., Goulden V., Wong G.A., Richard M.A., Anstey A., Wolf P. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch. Dermatol., 2007, vol. 143, no. 9, pp. 1131-1137.

11. Sukhova T.E., Tretyakova E.I., Khlebnikova A.N., Belova N.I. Experience of treatment of primary and recurrent basal cell carcinoma in the Moscow region. Topical issues of treatment of sexually transmitted infections and chronic dermatoses: proceedings of the scientific and practical conference, May 30-30, 2002. Yekaterinburg, 2002. (In Russian).

12. McCusker M., Basset-Seguin N., DummerR., Lewis K., Schadendorf D., Sekulic A., Hou J., Wang L., Yue H., Hauschild A. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur. J. Cancer, 2014, vol. 50, no. 4, pp. 774-783.

13. Snow S.N., Sahl W., Lo J.S., Mohs F.E., Warner T., Dekkinga J.A., Feyzi J. Metastatic basal cell carcinoma. Report of five cases. Cancer, 1994, vol. 73, no. 2, pp. 328-335.

14. Daniel-Bek K.V., Kolobyakov A.A. Malignant tumors of the skin and soft tissues. Moscow, Meditsina, 1979. 186 p. (In Russian).

15. STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma, 2019 г. Available at: https://clinicaltrials.gov/ct2/show/NCT01367665 (Accessed 15.01.2020).

Full-text article (in Russian)